Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for treatment of high-risk, early-stage triple-negative breast cancer: A network meta-analysis

Cortes J, Haiderali A, Huang M, Pan W, Fox GE, Park J, Frederickson AM, Fasching P, O'Shaughnessy J (2022)

Publication Type: Conference contribution

Publication year: 2022

Journal

Annals of Oncology Elsevier

Publisher: ELSEVIER

City/Town: AMSTERDAM

Pages Range: S615-S616

Conference Proceedings Title: ANNALS OF ONCOLOGY

Event location: Online

DOI: 10.1016/j.annonc.2022.07.204

Authors with CRIS profile

Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe

Involved external institutions

Merck & Co., Inc. / Merck Sharp & Dohme Corp (MSD) US United States (USA) (US) PRECISIONheor, LLC US United States (USA) (US) Baylor University (BU) US United States (USA) (US) International Breast Cancer Centre (IBCC) ES Spain (ES)

How to cite

APA:

Cortes, J., Haiderali, A., Huang, M., Pan, W., Fox, G.E., Park, J.,... O'Shaughnessy, J. (2022). Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for treatment of high-risk, early-stage triple-negative breast cancer: A network meta-analysis. In ANNALS OF ONCOLOGY (pp. S615-S616). Online: AMSTERDAM: ELSEVIER.

MLA:

Cortes, J., et al. "Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for treatment of high-risk, early-stage triple-negative breast cancer: A network meta-analysis." Proceedings of the Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Online AMSTERDAM: ELSEVIER, 2022. S615-S616.

BibTeX: Download